Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 11, 2007, Pages 15-22

  Faraone, Stephen V ^a,c   Wilens, Timothy E ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; COCAINE; DEXAMPHETAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NICOTINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VYVANSE;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COLLEGE STUDENT; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABUSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MISUSE; DRUG RELEASE; FOLLOW UP; HEALTH SURVEY; HUMAN; LONGITUDINAL STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; DELAYED-ACTION PREPARATIONS; FAMILY HEALTH; HUMANS; RISK FACTORS; SELF MEDICATION; SUBSTANCE-RELATED DISORDERS;

EID: 35348954367     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Wilens T. ADHD and the substance use disorders: the nature of the relationship, who is at risk, and treatment issues. Prim Psychiatry 2004;11:63-70
2. Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997;4:231-244
3. Wilens T, Adamson J, Sgambati S, et al. Do individuals with ADHD self medicate with cigarettes and substances of abuse? results from a controlled family study of ADHD. Am J Addict. In press
4. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 2001;49:258-267
5. Mannuzza S, Gittelman-Klein R, Horowitz-Konig P, et al. Hyperactive boys almost grown up, 4: criminality and its relationship to psychiatric status. Arch Gen Psychiatry 1989;46:1073-1079
6. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565-576
7. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? findings from a four year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997;36:21-29
8. Molina B, Pelham W. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 2003;112:497-507
9. Satterfield JH, Hoppe CM, Schell AM. A prospective study of delinquency in 110 adolescent boys with attention deficit disorder and 88 normal adolescent boys. Am J Psychiatry 1982;139:795-798
10. Katusic SK, Barbaresi WJ, Colligan RC, et al. Substance abuse among ADHD cases: a population-based birth cohort study. Presented at the annual meeting of the Pediatric Academic Societies; May 3-6, 2003; Seattle, Wash
11. Tarter RE, Edwards K. Psychological factors associated with the risk for alcoholism. Alcohol Clin Exp Res 1988;12:471-480
12. Brook JS, Cohen P, Brook DW. Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiatry 1998;37:322-330
13. Kellam SG, Ensminger ME, Simon MB. Mental health in first grade and teenage drug, alcohol, and cigarette use. Drug Alcohol Depend 1980;5:273-304
14. Glantz M, Pickens R. Vulnerability to Drug Abuse. Washington, DC: American Psychological Press; 1992
15. Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder: effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995;152:1652-1658
16. Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Arten Disord 2002;6:S31-S43
17. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001;21:RC121
18. Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2001;40:1352-1355
19. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 2000;9:77-97
20. Greenhill LL, Findling RL, Swanson JM. ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109:E39
21. Wolraich M, Greenhill LL, Pelham W, et al. Randomized controlled trial of OROS methylphenidate QD in children with attention deficit/hyperactivity disorder. Pediatrics 2001;108:883-892
22. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of Sli381 in children with attention deficit hyperactivity disorder. Pediatrics 2002;110:258-266
23. Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002;59:649-656
24. Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1491-1501
25. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD, 1: efficacy. J Am Acad Child Adolesc Psychiatry 1989;28:777-784
26. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-1321
27. Casat CD, Pleasants DZ, Schroeder DH, et al. Bupropion in children with attention deficit disorder. Psychopharmacol Bull 1989;25:198-201
28. Casat CD, Pleasants DZ, Van Wyck Fleet J. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull 1987;23:120-122
29. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000;10:311-320
30. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry 2001;40:230-235
31. Ernst M. MAOI treatment of adult ADHD. In: Program and Abstracts of the NIMH Conference on Alternative Pharmacology of ADHD; 1996; Washington, DC
32. Shekim WO, Davis LG, Bylund DB, et al. Platelet MAO in children with attention deficit disorder and hyperactivity: a pilot study. Am J Psychiatry 1982;139:936-938
33. Spencer T, Biederman J. Non-stimulant treatment for attention-deficit/ hyperactivity disorder. J Atten Disord 2002;6:S109-S119
34. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108:E83
35. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-120
36. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24:24-29
37. Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care. Medscape Psychiatry & Mental Health 2003;8:1-6
38. Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. Medscape General Medicine E Journal 2006;8:1-5
39. Wigal SB, Wigal TL, McGough JJ, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005;9:275-289
40. Faraone SV, Wigal S, Hodgkins P. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention-deficit/hyperactivity disorder. J Atten Disord. In press
41. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006;15:476-495
42. Wilens T, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? a meta-analytic review of the literature. Pediatrics 2003;111:179-185
43. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? J Clin Psychiatry 2003;64(suppl 11):9-13
44. Faraone SV, Biederman J, Wilens TE, et al. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med. In press
45. Sagvolden T, Russell VA, Aase H, et al. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1239-1247
46. Augustyniak PN, Kourrich S, Rezazadeh SM, et al. Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav Brain Res 2006;167:379-382
47. Musser CJ, Ahmann PA, Theye FW, et al. Stimulant use and potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatrics 1998;19:187-192
48. Marsh LD, Kay JD, Payne TP. Methylphenidate misuse in substance abusing adolescents. J Child Adolesc Subst Abuse 2000;9:1-14
49. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ 2001;165:1039-1044
50. Drug Enforcement Administration. Methylphenidate Review Document. Washington, DC: Office of Diversion Control, Drug and Chemical Evaluation Section; 1995
51. Low KG, Gendaszek AE. Illicit use of psychostimulants among college students: a preliminary study. Psychol Health Med 2002;7:283-287
52. Teter CJ, McCabe SE, Boyd CJ, et al. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 2003;23:609-617
53. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 2004;39:1095-1116
54. McCabe SE, Knight JR, Teter CJ, et al. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005;100:96-106
55. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs 2006;38:43-56
56. Teter CJ, McCabe SE, Cranford JA, et al. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 2005;53:253-262
57. Teter CJ, McCabe SE, Lagrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006;26:1501-1510
58. White BP, Becker-Blease KA, Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J Am Coll Health 2006;54:261-268
59. Wilens T, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408-414
60. Kroutil LA, Van Brunt DL, Herman-Stahl MA, et al. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend 2006;84:135-143
61. Wilens T, Monuteaux M, Snyder L, et al. The clinical dilemma of using medications in substance abusing adolescents and adults with ADHD: what does the literature tell us? J Child Adolesc Psychopharmacol 2005;15:787-798
62. Jaffe SL. Failed attempts at intranasal abuse of Concerta. J Am Acad Child Adolesc Psychiatry 2002;41:5
63. Kollins SH, Rush CR, Pazzaglia PJ, et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998;6:367-374
64. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909-1918
65. Stoops WW, Glaser PE, Rush CR. Reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans: a dose-response analysis. Drug Alcohol Depend 2003;71:179-186
66. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003;23:1281-1299
67. Spencer T, Biederman J, Ciccone P, et al. A PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short and long-acting orally administered formulations of methylphenidate in adults. Am J Psychiatry 2006;163:387-395
68. Spencer T, Rosenbaum J, Fischman AJ, et al. A PET study examining pharmacokinetics, likability, and dopamine transporter receptor occupancy of methylphenidate formulations in adults. Presented at the 43rd annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 2004; San Juan, Puerto Rico
69. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52:456-463
70. Volkow N, Wang G, Fowler J, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-1331
71. Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002;43:181-187
72. Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density is elevated in patients with ADHD. Lancet 1999;354:2132-2133
73. Krause K, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000;285:107-110
74. Aoyama T, Kotaki H, Sawada Y, et al. Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. Psychopharmacology (Berl) 1996;127:117-122
75. Aoyama T, Yamamoto K, Kotaki H, et al. Pharmacodynamic modeling for change of locomotor activity by methylphenidate in rats. Pharm Res 1997;14:1601-1606
76. Volkow ND, Wang GJ, Gatley SJ, et al. Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. Psychopharmacology (Berl) 1996;123:26-33
77. Boyle L, Moncrief S, Krishnan S. Pharmacokinetics of NRP 104 (lisdexamfetamine dimesylate) following administration of a single intranasal, intravenous, or oral dose in rate [poster]. Presented at the 46th annual New Clinical Drug Evaluation Unit Meeting; June 14, 2006; Boca Raton, Fla
78. Jasinski J, Krishnan S. Abuse liability of intravenous lisdexamfetamine dimesylate (LDX; NRP104) [poster]. Presented at the 19th annual Psychiatric and Mental Health Congress; November 17, 2006; New Orleans, La
79. Jasinski D, Krishnan S. A double-blind, randomized, placebo- and active-controlled, 6-period crossover study to evaluate the likability, safety, and abuse potential of lisdexamfetamine dimesylate (LDX) in adult stimulant abusers [poster]. Presented at the 19th Psychiatric and Mental Health Congress; November 18, 2006; New Orleans, La
80. Morrison JR. Adult psychiatric disorders in parents of hyperactive children. Am J Psychiatry 1980;137:825-827
81. Faraone SV, Biederman J, Keenan K, et al. A family-genetic study of girls with DSM-III attention deficit disorder. Am J Psychiatry 1991;148:112-117
82. Steinhausen HC, Nestler V, Huth H. Psychopathology and mental functions in the offspring of alcoholic and epileptic mothers. J Am Acad Child Psychiatry 1982;21:268-273
83. Wilens TE, Biederman J, Kiely K, et al. Pilot study of behavioral and emotional disturbances in the high-risk children of parents with opioid dependence. J Am Acad Child Adolesc Psychiatry 1995;34:779-785
84. Earls F, Reich W, Jung KG, et al. Psychopathology in children of alcoholic and antisocial parents. Alcohol Clin Exp Res 1988;12:481-487
85. Roizen NJ, Blondis TA, Irwin M, et al. Psychiatric and developmental disorders in families of children with attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1996;150:203-208
86. Zucker RA, Noll RB. The interaction of child and environment in the early development of drug involvement: a far ranging review and a planned very early intervention. Drugs Soc 1987;2:57-97
87. Rubio-Stipec M, Bird H, Canino G, et al. Children of alcoholic parents in the community. J Stud Alcohol 1991;52:78-88
88. Wilens T, Hahesy A, Biederman J, et al. Influence of parental SUD and ADHD on ADHD in their offspring: preliminary results from a pilot controlled family study. Am J Addict 2005;14:179-187
89. Morrison JR, Stewart MA. A family study of the hyperactive child syndrome. Biol Psychiatry 1971;3:189-195
90. Cantwell DP. Psychiatric illness in the families of hyperactive children. Arch Gen Psychiatry 1972;27:414-417
91. Manshadi M, Lippmann S, O'Daniel RG, et al. Alcohol abuse and attention deficit disorder. J Clin Psychiatry 1983;44:379-380
92. Faraone SV, Biederman J, Mick E, et al. Family study of girls with attention deficit hyperactivity disorder. Am J Psychiatry 2000;157:1077-1083
93. Milberger S, Faraone SV, Biederman J, et al. Familial risk analysis of the association between attention-deficit/hyperactivity disorder and psychoactive substance use disorders. Arch Pediatr Adolesc Med 1998;152:945-951